Photocure Partner Asieris announces CDE Approval for Hexvix Clinical Real-World Evidence Study in China
Press release – Oslo, Norway, March 11, 2022: Photocure ASA (PHO: OSE), The Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (688176.SH) has obtained approval to conduct a real-world evidence study for Hexvix[®] in Hainan, China, in addition to the Phase III study approved last month.Asieris announced today that the Hainan Provincial Medical Products Administration, in accordance with advice from the National Medical Products Administration Center for Drug Evaluation (CDE), has approved the inclusion of Hexvix in the clinical real-world evidence pilot study. In